Navigation Links
Welsh shingles drug set for final hurdle
Date:3/23/2010

A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.

A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy together with a virology group at the Rega Institute in Belgium and US biopharmaceutical company, Inhibitex Inc, is due to complete Phase II of its clinical trials.

If the drug completes Phase II it will enter the third and final stage which could see the drug being available to patients in less than three years.

Cardiff University's Professor of Medical Chemistry, Chris McGuigan, who led the team which discovered the new antiviral drug, said: "We are now entering the final and most crucial stage in the journey from the discovery of a new drug to the market.

"If we successfully complete this stage the drug would be available to help alleviate the pain and suffering for millions of shingles patients, not only in Wales but across the world."

Shingles is caused by the same viral infection that causes chicken pox. It is estimated that one-in-five people in the US, Europe and Japan will be affected by the condition during their lifetime.

The condition is characterised by skin lesions, blisters and rash, and acute pain, and in many cases, post-herpetic neuralgia which is a painful and often highly distressing condition resulting from nerve damage caused by the virus. Initial tests of FV-100 showed it has the potential to greatly reduce all of these symptoms.

In Phase I trials of FV-100, no serious adverse events in healthy volunteers were reported and data supported the potential for once-a-day dosing in future trials.Previous lab research has also shown the drug to be up to 10,000 times more potent against the virus than existing treatments.

Professor McGuigan added: "We believe this drug has the potential to be the most powerful inhibitor ever discovered to treat shingles.

"Each year only 15-20 new medicines are approved for clinical use and the chance of FV100 becoming an approved medicine improves the further we successfully progress through each of the clinical stages.

"We are incredibly excited at the prospect of FV-100 becoming commercially available in the future, and potentially being the first drug discovered in Cardiff University to make it to the marketplace."


'/>"/>

Contact: Chris Jones
JonesC83@cardiff.ac.uk
44-292-087-4731
Cardiff University
Source:Eurekalert

Related medicine news :

1. Welsh Tree LLC Proudly Presents the Release of the Celtic Pathways CD by Jason Evans, in Time for Saint Patrick's Day
2. Chicken Pox Shot Protects Against Shingles, Too
3. Chicken Pox Vaccine May Also Reduce Risk of Shingles Among Children
4. Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco
5. AKON Fragrance Finally Available at Akonfragrances.com
6. Morehead Associates, Inc. and Child Health Corporation of America (CHCA) Finalize Agreement for Employee and Physician Surveys and Consulting Services
7. Nine Healthcare Companies Named Finalists for Innovations in HealthcareSM ABBY Awards, to be Presented April 28th
8. 21 Healthcare Companies Achieve Semi-Finalist Status for Innovations in HealthcareSM ABBY Awards
9. Neovasc Completes Final Tranche of $1.537 Million Non-Brokered Private Placement
10. Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration
11. Kiwanis Selects Three Finalists for Worldwide Service Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Emergency rooms ... harder to find. Unfortunately, this can leave patients with dental emergencies at risk of ... is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... The campaign aims to ensure 2,50,532 ... reach the milestone of their 5 th birthday   --> ... between the ages of 2 - 5 years reach the ... campaign aims to ensure 2,50,532 children ... of their 5 th birthday   India , ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
(Date:2/9/2016)... YORK, Pa., Feb. 9, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced its financial results for ... 2015). ... Revenue for the ... million in the same period last year.  Cash receipts from customers ...
Breaking Medicine Technology: